openPR Logo
Press release

CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023 Report

05-04-2018 12:22 PM CET | Health & Medicine

Press release from: Kuick Resarch

CD Antigen Cancer Therapy Market Outlook and Clinical Trials

“CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023” report highlights:

* Market Opportunity Assessment: More than US$ 60 Billion by 2023
* Clinical and Patent Insight on 17 Commercialize CD Antigen Drugs
* Clinical and Licensing Insight on 184 CD Antigens in Clinical Pipeline
* Dosage and Price Analysis on Key Drugs
* Mechanism of CD Antigen Cancer Therapeutics
* Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
* Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase

Download Report Sample Weblink:

https://www.kuickresearch.com/report-cd-antigen-cancer-therapy-market-outlook-and-clinical-trials-insight-2023.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Introduction to CD Antigen Based Cancer Therapeutics
1.1 Prologue to CD Antigens
1.2 Background: Discovering CD Antigens in Cancer Therapy
1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics

2. Significance of CD Antigens: Normal Cells versus Cancer Cells
2.1 CD Antigens in Normal Cells
2.2 CD Antigens in Cancer

3. Working Mechanism of CD Antigen Based Cancer Therapeutics

4. Commercial Cancer Therapeutics Based on CD Antigens
4.1 Monoclonal Antibodies
4.2 Antibody Drug Conjugates
4.3 Bispecific Antibodies

5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics
5.1 CAR-T Cell Therapy
5.2 Aptamers
5.3 Immunoconjugates
5.3.1 Radio Immunoconjugate
5.3.2 Toxin Immunoconjugate
5.4 Novel CD Antigen Based Antibodies
5.4.1 Bispecific T-Cell Engager Antibody (BiTEs)
5.4.2 DART and TandAb

6. Major CD Antigens as Targets for Cancer Therapy
6.1 CD20
6.2 CD19
6.3 CD137
6.4 CD38
6.5 CD70
6.6 CD22
6.7 CD30
6.8 CD33
6.9 CD37

7. Major CD Antigens as Cancer Diagnostic Agents
7.1 CD20
7.2 CD5
7.3 CD56
7.4 CD66e
7.5 CD15
7.6 CD30
7.7 CD3

8. Major CD Antigens in Cancer Research
8.1 CD34
8.2 CD10
8.3 CD26
8.4 CD117
8.5 CD44
8.6 CD57

9. Global CD Antigen Based Therapeutics Market Overview
9.1 Market Progression
9.2 Current Market Scenario
9.3 Global CD Antigen Based Cancer Therapeutics Market Trends
9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview

10. Price and Dosage Analysis of Major CD Antigen Based Cancer Therapies
10.1 Rituximab (CD20)
10.2 Ofatumumab (CD20)
10.3 Obinutuzumab (CD20)
10.4 Daratumumab (CD38)
10.5 Brentuximab Vedotin (CD30)
10.6 Gemtuzumab Ozogamicin (CD33)
10.7 Inotuzumab Ozogamicin (CD22)
10.8 Ibritumomab Tiuxetan (CD20)
10.9 Blinatumomab (CD19, CD3)
10.10 Tisagenlecleucel (CD19)

11. Marketed Cancer CD Antigen Inhibitors Clinical and Patent Insight
11.1 Rituximab (MabThera and Rituxan)
11.2 Obinutuzumab (Gazyva and Gazyvaro)
11.3 Ibritumomab Tiuxetan (Zevalin and Zevamab)
11.4 Rituximab Biosimilar (AcellBia and USMAL)
11.5 Rituximab Biosimilar (Reditux and Tidecron)
11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima and Tuxella)
11.7 Rituximab Biosimilar (Novex)
11.8 Rituximab Biosimilar (RituxiRel, Toritz and Toritz RA)
11.9 Rituximab Biosimilar (Maball)
11.10 Rituximab Biosimilar (Kikuzubam)
11.11 Rituximab Biosimilar (Mabtas)
11.12 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat and Remniq)
11.13 Avelumab (BAVENCIO)
11.14 Pembrolizumab (Keytruda)
11.15 Atezolizumab (TECENTRIQ)
11.16 Durvalumab (Imfinzi)
11.17 Rituximab Biosimilar (Zytux)

12. Global CD Antigen Cancer Therapy Market Dynamics
12.1 Market Growth Drivers
12.1.1 Large Patient Base
12.1.2 Unmet Medical Need
12.1.3 Better Safety Profile
12.1.4 Accelerated Research and Development: Newly Identified CD Antigens in Cancer
12.1.5 Acquiring Major Share of the Modern Cancer Therapy Market
12.1.6 Strong Clinical Pipeline
12.2 CD Antigen Market Challenges
12.2.1 High Prices of CD Antigen Based Cancer Therapeutics
12.2.2 Difficulties in Differentiating CD Target on Cancer Cells
12.2.3 High Production Cost Due to Complex Structure

13. Global CD Antigens Cancer Therapy Market Future Forecast

14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I

15. Cancer CD 3 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
15.1 Preclinical
15.2 Phase-I
15.3 Phase-II

16. Cancer CD 4 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
16.1 Phase-I

17. Cancer CD 7 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
17.1 Preclinical

18. Cancer CD 19 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
18.1 Phase-I
18.2 Phase-I/II
18.3 Phase-II
18.4 Phase-III

19. Cancer CD 20 Antigen Inhibiors Clinical Pipeline by Company, Indication and Phase
19.1 Unknown
19.2 Research
19.3 Preclinical
19.4 Clinical
19.5 Phase-I
19.6 Phase-I/II
19.7 Phase-II
19.8 Phase-III
19.9 Registered

20. Cancer CD 22 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
20.1 Preclinical
20.2 Phase-III
20.3 Registered

21. Cancer CD 26 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
21.1 Preclinical
21.2 Phase-I/II

22. Cancer CD 27 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
22.1 Research
22.2 Preclinical
22.3 Phase-II

23. Cancer CD 30 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
23.1 Phase-I

24. Cancer CD 33 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
24.1 Phase-I
24.2 Phase-I/II

25. Cancer CD 38 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
25.1 Research
25.2 Preclinical
25.3 Phase-I/II
25.4 Phase-III

26. Cancer CD 44 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
26.1 Preclinical
26.2 Phase-I

27. Cancer CD 45 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
27.1 Phase-III

28. Cancer CD 46 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
28.1 Research

29. Cancer CD 47 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
29.1 Research
29.2 Preclinical
29.3 Phase-I
29.4 Phase-I/II


30. Cancer CD 52 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
30.1 Research
30.2 Preclinical

31. Cancer CD 55 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
31.1 Preclinical
31.2 Phase-II

32. Cancer CD 56 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
32.1 Phase-II

33. Cancer CD 66 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
33.1 Phase-I

34. Cancer CD 70 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
34.1 Phase-II

35. Cancer CD 71 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
35.1 Preclinical

36. Cancer CD 98 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
36.1 Phase-I

37. Cancer CD 200 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
37.1 Preclinical
37.2 Clinical
37.3 Phase-II

38. Cancer CD 223 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
38.1 Preclinical
38.2 Phase-I
38.3 Phase-I/II
38.4 Phase-II

39. Cancer CD 248 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
39.1 Preclinical
39.2 Phase-II

40. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
40.1 Research
40.2 Preclinical
40.3 Clinical
40.4 Phase-I
40.5 Phase-I/II

41. Cancer CD 319 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
41.1 Phase-I

42. Cancer Multiple Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
42.1 Preclinical
42.2 Phase-I
42.3 Phase-I/II
43. Competitive Landscape
43.1 AryoGen Biopharma
43.2 Biocad
43.3 Biogen Idec
43.4 Celltrion
43.5 Genentech
43.6 Genmab
43.7 GLYCART Biotechnology
43.8 Hetero Drugs
43.9 mAbxience
43.10 MedImmune
43.11 Merck
43.12 Sandoz
43.13 UCB

Figure 1-1: Evolution of CD Antigen Based Therapeutic Antibodies in Cancer Therapy
Figure 2 1: CD Antigens as Markers on Normal Leukocytes
Figure 2 2: Significance of CD Antigen in Cancer Cell and its Inhibition by Therapeutic Antibody
Figure 4-1: Types of CD Antigen Based Cancer Therapeutics
Figure 4-2: Structure of Monoclonal Antibody
Figure 4-3: Types of Therapeutic Monoclonal Antibodies
Figure 4-4: Architecture of Antibody Drug Conjugates
Figure 4-5: Bispecific Antibody Structure
Figure 5-1: Advanced CD Antigen Targeting Cancer Therapies
Figure 5-2: Structure of Radio Immunoconjugate
Figure 5-3: Structure of Bispecific T-Cell Engager Antibody
Figure 5-4: Structure of Dual Affinity Re-Targeting Antibody
Figure 6-1: Mechanism of Action of Anti-CD20 Monoclonal Antibody Rituximab
Figure 6-2: Mechanism of Action of Anti-CD30 Antibody Drug Conjugate Brentuximab Vedotin
Figure 9-1: Global - Cancer Therapeutic Monoclonal Antibody Market Share (%), 2017
Figure 9-2: Global - CD20 Cancer Therapeutic Segmentation by Region (%), 2017
Figure 9-3: Global - Rituximab Sales (US$ Billion), 2013-2016
Figure 9-4: Global - Ofatumumab Sales (US$ Million), 2013-2016
Figure 9-5: Global - Obinutuzumab Sales (US$ Million), 2015 and 2016
Figure 9-6: Global - Ibritumomab Tiuxetan Sales (US$ Million), 2013-2016
Figure 9-7: Global - Daratumumab Sales (US$ Million), 2015-2017*
Figure 9-8: Global - Daratumumab Half Yearly Sales (US$ Million), 2016 and 2017
Figure 9-9: Global - Brentuximab Vedotin Sales (US$ Million), 2014-2017
Figure 9-10: Global - Blinatumomab Sales (US$ Million), 2015-2017*
Figure 9-11: Global - Blinatumomab Sales (US$ Million), 2015-2017
Figure 9-12: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-13: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-14: Global - Cancer CD 3 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-15: Global - Cancer CD 3 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-16: Global - Cancer CD 19 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-17: Global - Cancer CD 19 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-18: Global - Cancer CD 20 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-19: Global - Cancer CD 20 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-20: Global - Cancer CD 22 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-21: Global - Cancer CD 22 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-22: Global - Cancer CD 26 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-23: Global - Cancer CD 26 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-24: Global - Cancer CD 27 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-25: Global - Cancer CD 27 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-26: Global - Cancer CD 33 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-27: Global - Cancer CD 33 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-28: Global - Cancer CD 38 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-29: Global - Cancer CD 38 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-30: Global - Cancer CD 44 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-31: Global - Cancer CD 44 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-32: Global - Cancer CD 47 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-33: Global - Cancer CD 47 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-34: Global - Cancer CD 52 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-35: Global - Cancer CD 52 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-36: Global - Cancer CD 55 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-37: Global - Cancer CD 55 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-38: Global - Cancer CD 200 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-39: Global - Cancer CD 200 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-40: Global - Cancer CD 223 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-41: Global - Cancer CD 223 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-42: Global - Cancer CD 248 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-43: Global - Cancer CD 248 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-44: Global - Cancer CD 274 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-45: Global - Cancer CD 274 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-46: Global - Cancer CD Miltiple Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-47: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (Number), 2017
Figure 9-48: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-49: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 10-1: US - Rituximab Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2017
Figure 10-2: US - Rituximab Vial Price by Quantity (US$), 2017
Figure 10-3: Rituximab Treatment Cost Analysis by Route of Administration (US$), 2017
Figure 10-4: US - Ofatumumab Intravenous Solution Price by Concentration (20mg/mL) (US$/Unit), 2017
Figure 10-5: US - Ofatumumab Vial Price by Quantity (US$), 2017
Figure 10-6: Ofatumumab - Treatment Dosage Analysis (mg)
Figure 10-7: Ofatumumab - Price Analysis by Dosage (US$)
Figure 10-8: Obinutuzumab First Cycle Dosage Analysis (mg)
Figure 10-9: Obinutuzumab Treatment Dosage Analysis (mg)
Figure 10-10: US - Obinituzumab Solution Price (US$), 2017
Figure 10-11: Obinutuzumab - Therapy First Cycle Average Cost (US$), 2017
Figure 10-12: Obinutuzumab Average Treatment Cost (US$), 2017
Figure 10-13: Daratumumab Monotherapy Dosage Analysis (mg)
Figure 10-14: Daratumumab Combination Therapy Dosage Analysis (mg)
Figure 10-15: US - Daratumumab Intravenous Solution Cost by Concentration (20mg/mL) (US$/Unit), 2017
Figure 10-16: Daratumumab Vial Price Analysis by Quantity (US$), 2017
Figure 10-17: Daratumumab Monotherapy Average Cost Analysis (US$), 2017
Figure 10-18: Daratumumab Combination Therapy Average Cost Analysis (US$), 2017
Figure 10-19: US - Brentuximab Vedotin Price Analysis, (US$), 2017
Figure 10-20: US - Brentuximab Vedotin Treatment Expenditure (US$), 2014
Figure 10-21: US - Brentuximab Vedotin Treatment Cost (US$), 2017
Figure 10-22: Global - Gemtuzumab Ozogamicin Treatment Cycle Price Analysis (US$), 2010 and 2017
Figure 10-23: US - Ibritumomab Tiuxetan Product and Dose Price Analysis (US$), 2017
Figure 10-24: US - Blinatumomab Dosage Average Price Analysis (US$), 2017
Figure 10-25: US - Blinatumomab Treatment First Cycle Average Cost (US$), 2017
Figure 10-26: US - Blinatumomab Treatment Subsequent Cycle Average Cost (US$), 2017
Figure 12-1: Global CD Antigen Based Cancer Therapy Market Driving Factors
Figure 12-2: Gemtuzumab vs Best Available Therapy Survival Rate
Figure 12-3: Global CD Antigen Based Cancer Therapeutic Market Challenges






Table 10-1: Rituximab Dosage Indications for Treatment of Different Cancer Conditions

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023 Report here

News-ID: 1039629 • Views: 256

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases


More Releases for Antigen

New HGH Saliva Antigen Covid Test gamechanger
An Austrian company HGH Disinfection und Cosmetique Gmbh, based in 9020 Klagenfurt created with a Korean partner a unique antigen salvia test unit which is so simple that anybody can use it. Till now mass testing was nasal stick by government and doctors. Now this new test unit can be used by everybody without a scarry stick in the nose and a result with 95% is ready in 10
p53 Antigen Modulators Therapeutics- Pipeline Analysis 2018 |
p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1195 Thus, new opportunities in cancer immunotherapy are expected to develop better drug candidates targeting p53, with complete understanding of interactions between p53 and the immune system, to avoid various
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
ReportsWorldwide has announced the addition of a new report title Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also
CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerT …
ReportsWorldwide has announced the addition of a new report title CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerTestis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) -
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
Market Research Hub (MRH) added a new research report to its vast database titled “Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Pipeline Review, H2 2017” targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion
B-Cell Maturation Antigen Targeted Therapies Market
Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma.